ASH 2019: Results of a phase II study examining zanubrutinib for treatment of relapsed marginal zone lymphoma.
Home / Resource Library / Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma
ASH 2019: Results of a phase II study examining zanubrutinib for treatment of relapsed marginal zone lymphoma.